ERBB2 and breast cancer: Currently, a clinical trial is underway to assess the safety, tolerability, pharmacokinetics, and efficacy of HS‐10352 in combination with fulvestrant in patients with PIK3CA‐mutant, HR‐positive, HER2‐negative advanced breast cancer (NCT05504213).